Terminal double-substituted triazole Schiff base compound, its preparation method and use

Abstract

The invention relates to the field of thrombotic disease related drugs, belongs to triazole Schiff base compounds with brand new structures and derivatives of the triazole Schiff base compounds and particularly relates to PAR (Protease Activated Receptor)-1 antagonists with terminally-disubstituted triazole Schiff base structures, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases. All the substituent groups are defined as the specification.

Description

technical field

[0001] The invention relates to the field of drugs related to thrombosis diseases. The present invention belongs to a class of triazole Schiff base compounds and their derivatives with a new skeleton, in particular, it relates to a class of PAR-1 antagonistic triazole Schiff base structures with terminal double substitutions that have a therapeutic effect on thrombotic diseases Agents and their preparation methods, and pharmaceutical compositions containing them. Background technique

[0002] Protease Activated Acceptor-1 (PAR-1) is a new target of anti-platelet antithrombotic drugs discovered recently. Protease-activated receptor 1 is also called thrombin receptor. After thrombin is activated by the coagulation chain, it acts on platelets through PAR-1 receptors to activate platelets, causing platelet aggregation and causing thrombus and coagulation. The thrombus induced by PAR-1 is rich in platelet components, which is the main cause of arterial thrombus....

Images